Home World News A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with Relapsed... World News A Combination of Teclistamab and Daratumumab Prolongs PFS in Patients with Relapsed or Refractory Multiple Myeloma By Ogkologos - January 12, 2026 486 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR Embracing Bravery When You Have a Genetic Cancer Disease January 13, 2021 Mental Health Awareness for Health Care Providers May 21, 2021 Outcome of EMA Assessment on Use of Lutetium (177Lu) in Treatment... October 15, 2025 Women in science: Cancer research pioneers – part 1 January 18, 2023 Load more HOT NEWS Breaking: Longtime Broadcast Journalist Cokie Roberts Dies At 75 A career forged in team science ESMO contributes to discussions on the future of cancer care at... FDA Approves Nivolumab and Hyaluronidase-nvhy for Subcutaneous Injection
